Microislet News (AMEX:MII)
| Latest Microislet News Headlines | | Date | Time | Source | | | 01/16/2007 | 8:00AM | PRNUS | MicroIslet Receives $2 Million Capital Infusion From Chairman
SAN DIEGO, Jan. 16 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII), a biotechnology company engaged in the development and commercialization of patented technologies in transplantation therapy for people with insulin-dependent diabetes, today announced that the Chairman of its Board of Directors, John J. Hagenbuch... More...>> |
| 12/13/2006 | 8:00AM | PRNUS | MicroIslet Holds Positive Pre-IND Meeting With FDA
* Company preparing for IND filing toward trials of insulin-producing islet allotransplantation therapy to combat diabetes
SAN DIEGO, Dec. 13 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII), a biotechnology company engaged in the research, development and commercialization of patented technologies in transplantation... More...>> |
| 11/30/2006 | 8:00AM | PRNUS | MicroIslet Expands Expertise in Product Development
* Two Key Hires Are Added to Support Initiation of Human Trials
SAN DIEGO, Nov. 30 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII), a biotechnology company engaged in the research, development and commercialization of patented technologies in transplantation therapy for people with insulin-dependent diabetes... More...>> |
| 11/08/2006 | 8:00AM | PRNUS | MicroIslet Poster Presentations Accepted at Levine Diabetes Symposium
- Presentations highlight the Company's plan to address immuno-response and islet supply limitations of the Edmonton Protocol
SAN DIEGO, Nov. 8 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII), a biotechnology company engaged in the research, development and commercialization of patented technologies in transplantation... More...>> |
| 11/08/2006 | 8:00AM | PRNUS | MicroIslet Poster Presentations Accepted at Levine Diabetes Symposium
- Presentations highlight the Company's plan to address immuno-response and islet supply limitations of the Edmonton Protocol
SAN DIEGO, Nov. 8 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII), a biotechnology company engaged in the research, development and commercialization of patented technologies in transplantation... More...>> |
| 10/18/2006 | 8:30AM | PRNUS | MicroIslet Comments on NIH Plan to Combat Type 1 Diabetes
* CEO Sees NIH Objective to Develop Cell Replacement Therapy as 'Closely Aligned With MicroIslet's Therapeutic Strategy'
SAN DIEGO, Oct. 18 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII), a biotechnology company engaged in the research, development and commercialization of patented technologies in transplantation... More...>> |
| 09/06/2006 | 8:00AM | PRNUS | MicroIslet to Webcast Presentation at Oppenheimer Diabetes Conference
SAN DIEGO, Sept. 6 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII), a biotechnology company engaged in the research, development and commercialization of patented technologies in transplantation therapy for people with insulin-dependent diabetes, today announced that will present an update on the Company's islet... More...>> |
| 08/07/2006 | 6:00AM | PRNUS | MicroIslet Transplantation Studies in Diabetic Primates Successful at Six-Month Milestone
SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII), a biotechnology company engaged in the research, development and commercialization of patented technologies in transplantation therapy for people with insulin-dependent diabetes, today announced that primate subjects in ongoing studies have continued... More...>> |
| 07/05/2006 | 8:30AM | PRNUS | MicroIslet Added to Russell Microcap(TM) Index
SAN DIEGO, July 5 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII) announced today that its stock has been added to the Russell Microcap(TM) Index.
"We are pleased with the inclusion of MicroIslet in the prestigious Russell Microcap Index," commented James R. Gavin III, M.D., Ph.D., MicroIslet's President and... More...>> |
| 06/09/2006 | 3:26PM | PRNUS | MicroIslet Appoints Dr. James R. Gavin III President and CEO
Former President of the American Diabetes Association and Internationally Recognized Diabetes Expert Has Served as MicroIslet's Interim President and CEO Since January 2006
SAN DIEGO, June 9 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII) is pleased to announce today that Dr. James R. Gavin III, M.D., Ph.D, who... More...>> |
| 05/11/2006 | 12:03PM | PRNUS | MicroIslet to Present at Rodman & Renshaw Global Healthcare Conference
SAN DIEGO, May 11 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII), a biotechnology company engaged in the research, development and commercialization of patented technologies in transplantation therapy for people with insulin-dependent diabetes, announced today its scheduled presentation at Rodman & Renshaw's... More...>> |
| 04/12/2006 | 8:30AM | PRNUS | MicroIslet Announces Encouraging Data From Islet Transplantation Studies in Primates
SAN DIEGO, April 12 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII), a biotechnology company engaged in the research, development and commercialization of patented technologies in transplantation therapy for people with insulin-dependent diabetes, today announced encouraging data from preclinical primate studies.
The... More...>> |
| 04/11/2006 | 12:52PM | PRNUS | MicroIslet, Inc. Files Annual Report on Form 10-KSB for 2005 and Updates Cash Position
SAN DIEGO, April 11 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII) today announced that it filed its Annual Report on Form 10-KSB for the year ended December 31, 2005 with the Securities and Exchange Commission on April 6, 2006. The Company reported a net loss of $8.5 million in 2005 compared to $6.5 in 2004... More...>> |
| 03/31/2006 | 7:47PM | PRNUS | MicroIslet Announces Delay in Filing of Annual Report on Form 10-KSB for Fiscal Year Ended December 31, 2005
SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII), a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for people with insulin-dependent diabetes, today announced that it will not file its Annual Report... More...>> |
| 03/21/2006 | 5:13PM | PRNUS | MicroIslet Appoints Bertram Walls, MD, to Board of Directors
Regains Compliance With American Stock Exchange Continued Listing Standards
SAN DIEGO, March 21 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII), a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for people with insulin-dependent... More...>> |
| 01/19/2006 | 4:05PM | PRNUS | MicroIslet Appoints Dr. James R. Gavin III Interim President and CEO
Internationally Recognized Diabetes Expert Is Former President of the American Diabetes Association
SAN DIEGO, Jan. 19 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII) today announced that it has appointed James R. Gavin III, M.D., Ph.D., as its interim President and CEO, effective January 20, 2006. Dr. Gavin has... More...>> |
| 12/27/2005 | 8:00AM | PRNUS | MicroIslet to Advance Product Development with Definitive Agreement for $3.4 Million Private Placement
SAN DIEGO, Dec. 27 /PRNewswire-FirstCall/ -- MicroIslet Inc. (AMEX:MII) announced today that it has entered into agreements for the sale of common stock for gross proceeds of approximately $3.4 million. The purchasers include new and existing institutional and other accredited investors. The company has agreed to sell... More...>> |
| 11/25/2005 | 8:00AM | PRNUS | MicroIslet Announces Addition of New Members to Its Scientific Advisory Board
SAN DIEGO, Nov. 25 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII), announced today the appointment of new members to its Scientific Advisory Board. With the addition of Dr. Nora E. Sarvetnick, Dr. Athanassios Sambanis, and Dr. Bassam Damaj to the advisory board, MicroIslet has enlisted a team of the world's... More...>> |
| 11/22/2005 | 7:17PM | PRNUS | MicroIslet Reports Third Quarter Financial Results
SAN DIEGO, Nov. 22 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII) has announced financial results for the period ended September 30, 2005.
For the quarter ended September 30, 2005, the company reported a net loss of $1,915,168 or $0.05 per share compared with a net loss of $1,412,257 or $0.04 per share, for... More...>> |
| 11/22/2005 | 8:00AM | PRNUS | MicroIslet Announces Long-Term Supply Agreement With Mayo Foundation
SAN DIEGO, and ROCHESTER, Minn., Nov. 22 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII) and Mayo Foundation for Medical Education and Research ("Mayo") today announced that they have entered into a long-term strategic supply agreement under which Mayo will supply Designated Pathogen Free ("DPF") Pigs to MicroIslet... More...>> |
|
|
|